ASH2023 Archives - MediaMedic

Exploration of Blinatumomab and Reduced Dosing of Cyclophosphamide before and after Allogeneic Hematopoietic Stem Cell Transplantation

By Peter W. PENG 2024.01.05

The 65th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from December 9 to 12, 2023. ASH Annual Meeting is the largest and most comprehensive international event covering both basic and clinical research in hematology. This year, the Hematology Department at West China Hospital, Sichuan University, presented two oral reports, and we delve into these studies

ASH 2023丨Professor Lin Tongyu: Decoding ASH Conference Insights on Lymphoma Treatment, Potential Revealed in r/r-PTCL with EZH1/2 Inhibitor HH2853

By Mourabit Halima 2024.01.05

From December 9 to 12, the highly anticipated 65th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA. Focused on the annual pinnacle in the field of hematologic malignancies, the front-line reporting team of "Oncology Insights" delved into the forefront, witnessing the outstanding performance of "China's Good Voice" on the international stage. In the realm of aggressive lymphomas, advancements in targeted and cellular immunotherapy continue to dominate. To comprehensively grasp the lymphoma treatment developments at this ASH conference, "Oncology Insights" had the privilege of interviewing Professor Lin Tongyu from Sun Yat-sen University Cancer Hospital, who provided insightful analysis on the topic.

ASH in 5 Minutes | Prof. An Gang: Immunotherapy Dominates MM Research, Exploration of Drug Resistance Mechanisms Vital

By Mourabit Halima 2024.01.05

Currently, the highly anticipated 65th American Society of Hematology (ASH) Annual Meeting is underway in San Diego, USA. In the face of the annual pinnacle event in the field of hematologic malignancies, the front-line reporting team of "Hematology Frontier" delves deep, capturing the international cutting-edge developments and witnessing the outstanding performance of "China's good voice" on the global stage. In the realm of Multiple Myeloma (MM), advancements in targeted therapy and cell immunotherapy continue to dominate, making it imperative to comprehensively grasp the therapeutic progress at this year's ASH conference. "Hematology Frontier" had the privilege of interviewing Professor An Gang from the Hematology Hospital of the Chinese Academy of Medical Sciences, who brilliantly dissected the progress in MM.

ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment

By Mourabit Halima 2024.01.05

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening blood disorder. Due to the complexity of complement biology and various pathogenic pathways, there remains a significant unmet clinical need, urgently requiring next-generation drugs with superior efficacy and dosing convenience compared to current therapies. At the recently held 65th American Society of Hematology (ASH) Annual Meeting, Prof. Fengkui Zhang from the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology) and Prof. Bing Han's team from Peking Union Medical College Hospital presented an oral report (Abstract: 572). The study explored the safety and effectiveness of the dual-function C5 antibody/H factor fusion protein KP104 in PNH patients who had not received complement inhibitor treatment. This research brings hope to address this challenging issue and has been selected as a highlight of "ASH 2024." The summarized details are presented below in this issue of "Hematology Insight."

ASH 2023 | Professor Hu Yongxian: Achieving Deep Remission in Newly Diagnosed Acute Lymphoblastic Leukemia Patients with a Chemotherapy-Free Regimen

By Mourabit Halima 2024.01.05

The 65th Annual Meeting of the American Society of Hematology (ASH) was held from December 9-12, 2023, in San Diego, USA. ASH Annual Meeting is the largest and most comprehensive international event in the field of hematology, showcasing the latest and most advanced research developments in hematology over the past year. It plays a crucial role in driving the development of the diagnosis and treatment of hematological diseases. During the conference, Tumor Insights interviewed Professor Hu Yongxian from the First Affiliated Hospital of Zhejiang University School of Medicine. Professor Hu provided detailed information about the excellent results of the sequential dasatinib maintenance therapy with VP+dasatinib+2 rounds of CAR-T cell treatment for newly diagnosed acute lymphoblastic leukemia, which was presented at the conference. This outcome is expected to have a profound impact on clinical practice. The information is compiled below for reference.

$ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma$

ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma

By Mourabit Halima 2024.01.05

In the just-concluded 65th American Society of Hematology (ASH) Annual Meeting, CAR-T therapy emerged as a crucial advancement in the treatment of Multiple Myeloma (MM). The only approved BCMA CAR-T in China, Idecabtagene Vicleucel (CT103A), shone brightly. Professor Chunrui Li and her team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, presented a study (abstract 761) reporting the efficacy and safety data of CT103A in refractory/relapsed MM, garnering widespread attention. "Tumor Insights" had the privilege of interviewing Professor Li at the event, delving deep into the advancements in MM treatment and future directions

Efficacy of Hetrombopag Combined with Cyclosporine A in the Treatment of Transfusion-Dependent Non-Severe Aplastic Anemia

By Mourabit Halima 2024.01.05

The optimal treatment for transfusion-dependent non-severe aplastic anemia (TD-NSAA) remains uncertain. While UK guidelines recommend intensified immunosuppressive therapy (IST) as a first-line treatment for TD-NSAA, the associated costs and risks are relatively high. A recent study conducted by Professor Guangsheng He's team at Jiangsu Provincial People's Hospital, presented at the 65th American Society of Hematology (ASH) Annual Meeting, explored the effectiveness of Hetrombopag combined with Cyclosporine A (CsA) in treating TD-NSAA. The study provides crucial insights for clinical consideration. Here is a summary.

2023 ASH丨Professor Jiang Qian: Discussing Drug Resistance in Chronic Myeloid Leukemia (CML) Treatment and the Value of Novel TKIs

By Mourabit Halima 2024.01.04

The 65th Annual Meeting of the American Society of Hematology (ASH) recently concluded, with significant contributions in the field of Chronic Myeloid Leukemia (CML) treatment. Professor Jiang Qian and her team from Peking University People's Hospital presented multiple studies, with abstracts 867 and 869 selected for oral presentations. These reports highlighted the potential of TGRX-678 and Olverembatinib in CML treatment and overcoming drug resistance. "Hematology Frontier" had the privilege of interviewing Professor Jiang Qian on these topics.

BCMA/CD19 Dual-Target FasTCAR-T Cells Efficient and Safe in First-Line Treatment of High-Risk Newly Diagnosed Multiple Myeloma Patients

By Peter W. PENG 2024.01.04

At the 65th American Society of Hematology Annual Meeting in 2023 (ASH), Professor Du Juan and her team from Shanghai Changzheng Hospital presented preliminary findings from a Phase I study (abstract 1022) assessing the efficacy and safety of BCMA/CD19 dual-target FasTCAR-T cells (GC012F) in treating high-risk, newly diagnosed multiple myeloma (HR-NDMM) patients. The study was selected for oral presentation at the conference. In this article, "Tumor Insight" has compiled the abstract content and invited Professor Du Juan to provide commentary for readers' reference.